Research progress of primary testicular lymphoma and primary central nervous system lymphoma: reports from the 19th European Hematology Association annual congress
10.3760/cma.j.issn.1009-9921.2014.10.004
- VernacularTitle:原发性睾丸淋巴瘤及原发性中枢神经系统淋巴瘤研究进展:第19届欧洲血液学会年会报道
- Author:
Yifan PANG
;
Xiaoyan KE
- Publication Type:Journal Article
- Keywords:
Primary testicular lymphoma;
Primary central nervous system lymphoma;
European Hematology Association annual congress
- From:
Journal of Leukemia & Lymphoma
2014;23(10):586-588,592
- CountryChina
- Language:Chinese
-
Abstract:
Primary testicular lymphoma (PTL) is an uncommon extranodal lymphoma,with an aggressive clinical course and poor outcome.A combined treatment with full-course anthracycline-based chemotherapy with rituximab and central nervous system prophylaxis with intrathechal methotrexate and contralateral testicular radiotherapy should be considered as the standard of care at limited stage.These patients have a very high risk of central nervous system recurrence and the addition of systemic central nervous system prophylaxis with intravenous methotrexate may be the best treatment option.Primary central nervous system lymphoma (PCNSL) is an aggressive disease with a dismal prognosis,particularly when treated with established protocols used for systemic non-Hodgkin lymphoma.Use of methotrexate in combination with cytarabine has been proposed as a standard induction regimen.The role of the anti-CD20 antibody has not yet been defined,however,phase Ⅰ and Ⅱ trials suggest its efficacy despite low penetration within the cerebrospinal fluid.High-dose chemotherapy followed by autologous stem cell transplantation has shown high remission rates with 3-year overall suvival rates of up to 87 ％.
